<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05059912</url>
  </required_header>
  <id_info>
    <org_study_id>CD7T</org_study_id>
    <nct_id>NCT05059912</nct_id>
  </id_info>
  <brief_title>CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma</brief_title>
  <official_title>Humanized CD7 CAR T-cell Therapy for R/R CD7+ T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Jiangnan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Zhongshan Hospital of Dalian University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, multiple center and single arm phase 2 study to evaluate&#xD;
      the efficacy and safety of T cells expressing humanized CD7 chimeric antigen receptors&#xD;
      treatment for patients with refractory/relapsed CD7 positive T cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2021</start_date>
  <completion_date type="Anticipated">August 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 3, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients who achieved response (complete response and partial response ) after treatment of CD7 CAR-T cell. Response will be assessed using the Lugano criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events are evaluated with CTCAE V5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete relapse rate(CR)</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients who achieved complete response after treatment by CD7 CAR-T cell.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response (DOR)</measure>
    <time_frame>1 year</time_frame>
    <description>Duration of overall response will be assessed from the CAR-T cell infusion to progression, death or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>PFS will be assessed from the CAR-T cell infusion to progression, death or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>1 year</time_frame>
    <description>OS will be assessed from the CAR-T cell infusion to death or last follow-up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Refractory and Relapsed T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>CD7 positive relapsed or refractory T cell lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Humanized CD7 CAR-T cells intravenously infused to patient with R/R T-NHL[ at a dose of (0.5- 5)x10^6 CD7 CAR-T cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Humanized CD7 CAR-T cells</intervention_name>
    <description>Patients will receive infusion of CAR T-cells targeting CD7 to confirm the safety and efficacy of CD7 CAR T-Cells in CD7+ relapsed or refractory T cell lymphoma</description>
    <arm_group_label>CD7 positive relapsed or refractory T cell lymphoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. R/R T-NHL with measurable (≧1.5cm) lesions confirmed by pathological&#xD;
             immunohistochemistry or flow cytometry&#xD;
&#xD;
          3. The expressions of both CD4 and CD8 are negative in patients with bone marrow involved&#xD;
&#xD;
          4. The Eastern Cooperative Oncoloy Group (ECOG) physical condition score ≤ 2 points&#xD;
&#xD;
          5. The main organ functions need to meet the following conditions:&#xD;
&#xD;
             A.Left ventricular ejection fraction ≥50% B.Creatinine ≤132umol/l or creatinine&#xD;
             clearance ≥60 ml/min C.ALT and AST≤2.5 upper limitation of normal D.T-BIL≤2.0mg/dl&#xD;
             E.SpO2 &gt; 90%&#xD;
&#xD;
          6. Results of pregnant test should be negative, and agree to conception control during&#xD;
             treatment and 1 year after CAR-T infusion&#xD;
&#xD;
          7. Expected survival exceeds 3 months&#xD;
&#xD;
          8. Written informed consent could be acquired&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Immunosuppressant medications or steroids were used within 2 weeks before cell&#xD;
             collection, or need to use steroids or immunosuppressant medications more than two&#xD;
             years&#xD;
&#xD;
          2. Patients with uncontrolled active infection&#xD;
&#xD;
          3. Active hepatitis B or hepatitis C infection&#xD;
&#xD;
          4. Patients with HIV infection&#xD;
&#xD;
          5. Severe acute or chronic graft-versus-host disease (GVHD)&#xD;
&#xD;
          6. Participated in any other drug research clinical trials within 30 days before&#xD;
             enrollment&#xD;
&#xD;
          7. Prior CAR-T cells therapy within 3 months before enrollment&#xD;
&#xD;
          8. Prior allogeneic hematopoietic stem cell transplantation within 6 months before&#xD;
             enrollment&#xD;
&#xD;
          9. Uncontrolled other tumor&#xD;
&#xD;
         10. Women in pregnancy, lactation or planning to become pregnant&#xD;
&#xD;
         11. The researcher considers inappropriate to participate in this research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Depei Wu, M.D&amp;Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caixia Li, M.D</last_name>
    <phone>+86 512 67781856</phone>
    <email>licaixia@suda.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jia Chen, M.D</last_name>
    <phone>+86 512 67781856</phone>
    <email>chenjiasuzhou@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Depei Wu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

